Skip to main content

Table 2 Baseline characteristics and antibody titers among patients treated with anti-inflammatory treatment and matched control

From: Humoral response among patients with interstitial lung disease vaccinated with the BNT162b2 SARS-Cov-2 vaccine: a prospective cohort study

  Anti-inflammatory Treatment
(n = 29)
Matched Control
(n = 29)
P value
Age, median (IQR), y 67 (55–73) 70 (56–72) 0.86
Male sex (%) 11 (38) 11 (38) 1.0
Anti-inflammatory treatment
 Antimetabolites and OCS 21 NA
 Rituximab 8
 Daily OCS dose (mg), median (IQR) 8 (5–8)
 Daily mycophenolate mofetil dose (g), median (IQR) 2 (1–2)
 Rituximab doses, median (IQR) 3 (2–4)
 Days post last rituximab treatment, median (IQR) 123 (36–147)
IgG titer, median (IQR), Au/ml 39.60 (4.25–165) 970.10 (505–1926)  < 0.001
IgG titer GMT (SD) 23.70 ± 12.73 1006.93 ± 2.45  < 0.001
Seropositive (%) 14 (48.3) 29 (100)  < 0.001
Days post vaccination, median (IQR) 179 (168–184) 137 (122–158)  < 0.001
  1. OCS: Oral glucocorticoid